TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07595965: A Phase I Clinical Trial to Evaluate the Safety and Tolerability of Allogeneic Bone Marrow-derived Mesenchymal Stem Cells in Patients With Severe Anti-aqua Porin-4-immunoglobulin G Positive Neuromyelitis Optica Spectrum

Sponsor: Corestemchemon, Inc. · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 20 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$5,090,820

Rescue Site Savings

+$3,354,780

Unlock Full NCT07595965 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07595965 Rescue Dossier →